BMO Capital initiates coverage on Affimed Therapeutics (NASDAQ: AFMD) with a Outperform rating and a price target of $13.00.Analyst Jim ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE